ReviewMolecular medicine reports2021
Acute spinal cord injury: Pathophysiology and pharmacological intervention (Review).
Review in Molecular medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 83 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The neuroprotective and therapeutic potential of resveratrol for traumatic spinal cord injuries: a systematic review.BMC neurology · 2026Pooled it
- Assessment of mesenchymal stem cells for the treatment of spinal cord injury: a systematic review and network meta-analysis.Frontiers in cellular neuroscience · 2025Pooled it
- Electroacupuncture ameliorates cognitive impairment after spinal cord injury via BDNF/TrkB/CREB-mediated hippocampal neurorestoration.IBRO neuroscience reports · 2026Article
- Brain-spine interface: an exploration of a potential future treatment for spinal cord injury.Neurosurgical review · 2026Review
- A Primary Spinal Cord Mixed Culture Method for In Vitro Analysis of Glial Heterogeneity and Inflammatory Responses.Neurochemical research · 2026Article
- Advances in Hydrogel Tissue Engineering for Spinal Cord Injury Repair.Smart medicine · 2026Review
- Article
- PTGS2 as a potential target for apigenin to promote spinal cord injury repair.Journal of bioenergetics and biomembranes · 2026Article
- Exosome-loaded hydrogel systems for spinal cord injury repair: mechanisms, advancements, and future directions.Journal of materials science. Materials in medicine · 2026Review
- Combined Neuroprotective Effects of N,N-Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats.Journal of neurochemistry · 2026Article
- Ferroptosis in Spine-Related Diseases: Mechanistic Insights and Potential Therapeutic Targets.Cellular and molecular neurobiology · 2026Review
- Kaempferide Promotes Neuroprotection and Functional Recovery After Spinal Cord Injury and is Associated with Differential Regulation of ARG1, CA4, CYP1B1, and OAT.Neuropsychiatric disease and treatment · 2026Article
- AAD-2004 through clearing HScientific reports · 2025Article
- Removal or inhibition of transglutaminase 2 decreases cellular stress, supporting tissue preservation, and recovery after SCI.Acta neuropathologica communications · 2025Article
- FGFs/FGFRs and neuroinflammatory diseases: mechanism, drug therapies and delivery systems.Journal of advanced research · 2025Review
- Biomaterials and cell-based therapy post spinal cord injury.Journal of translational medicine · 2025Review
- The Utility of Metabolomics in Spinal Cord Injury: Opportunities for Biomarker Discovery and Neuroprotection.International journal of molecular sciences · 2025Review
- Enhancing Functional Recovery After Spinal Cord Injury Through Neuroplasticity: A Comprehensive Review.International journal of molecular sciences · 2025Review
- Ginsenoside Rh2 alleviates inflammatory response and enhances motor function recovery in spinal cord injury mice via the ROS/MAPK14 signaling pathway.Journal of ginseng research · 2025Article
- Perioperative management in acute and chronic spinal cord injury, narrative review.Journal of anesthesia, analgesia and critical care · 2025Review
23 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) is one of the most debilitating of all the traumatic conditions that afflict individuals. For a number of years, extensive studies have been conducted to clarify the molecular mechanisms of SCI. Experimental and clinical studies have indicated that two phases, primary damage and secondary damage, are involved in SCI. The initial mechanical damage is caused by local impairment of the spinal cord. In addition, the fundamental mechanisms are associated with hyperflexion, hyperextension, axial loading and rotation. By contrast, secondary injury mechanisms are led by systemic and cellular factors, which may also be initiated by the primary injury. Although significant advances in supportive care have improved clinical outcomes in recent years, a number of studies continue to explore specific pharmacological therapies to minimize SCI. The present review summarized some important pathophysiologic mechanisms that are involved in SCI and focused on several pharmacological and non‑pharmacological therapies, which have either been previously investigated or have a potential in the management of this debilitating injury in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.